Skip to content
TESCT — Trans European Stem Cell Therapy Society
Delegates at a TESCT work meeting

6th work meeting

Lake Biel, Switzerland

The patient-role meeting: what patients actually need, how industry could become a trusted partner rather than a cost, and the state of the art in cell-based therapy.

Dates
8–11 September
Venue
Lake Biel, Switzerland
Convened by
Dr. Marco Traub

Programme

What was discussed

  1. 01

    European Innovation Partnership on Active and Healthy Ageing

  2. 02

    Involvement and identification of specific aims towards patients' role

  3. 03

    Stem cell and drug safety, and epigenetic profiling

Specific topics

  • What are the patient-orientated needs, with a focus on quality of life and satisfaction?
  • How could the role of the pharmaceutical industry change from drug producer and target for juridical trials to a respected patient partner?
  • What significant measures are important to improve communication between patients, health policy, industry and regulators beyond the marketing level?
  • How could patients be better informed with the implementation of IT technology?
  • What are the measures to track down changes in patients' satisfaction?
  • How to generate efficiently the paradigm change from weighting clinical indicators such as surrogate response and endpoints for quality of life towards individualised and regenerative medicine, with bench-to-bed approaches in integrated scenarios?
  • What is the potential of stem cell technology concerning drug safety?
  • What is the state-of-the-art status of cell-based therapies in clinical practice?
  • Does regenerative medicine offer the solution for “long live living” in dignity?

Dr. Mary Baker, MBE — in her words

“The sad thing is that pharma companies are not involved in the major health systems; they're peripheral. They should not be seen as a cost, they should be seen as a trusted partner.”

Speakers

Who spoke

  • Dr. Mary Baker, MBE

    Management Board of the European Medicines Agency (EMEA); Chair of the Working Group on Parkinson's Disease

  • Thomas Bols

    Vice President, Corporate Affairs EU, Biogen International GmbH, Switzerland

  • Marco Cappato

    Segretario dell'Associazione Luca Coscioni; Member of the City Council of Milan, Italy

  • Prof. Tomas J. Ekström

    Department of Clinical Neuroscience, Karolinska Institutet, Sweden

  • Prof. Miomir Knezevic

    National Institute of Biology, University of Ljubljana, Slovenia

  • Dr. Jeya Prakash

    Age Management Consultant, Harley Street, London

  • Dr. Thomas Syburra

    Senior Consultant Cardiac Surgeon, Lucerne Kantonsspital, Switzerland; Major, Swiss Air Force

  • Prof. Ralf Tönjes

    Paul-Ehrlich-Institut, Division of Medical Biotechnology, Germany; Goethe University, Frankfurt am Main

  • Dr. Marco Traub

    Project Coordinator and CEO, TESCT, Berne and London